Artelo Biosciences to present ART26.12 at BIO-Europe 2026

Artelo Biosciences said it was selected for its first company presentation at BIO-Europe 2026, to showcase clinical progress and results from its first clinical study of ART26.12. The company also plans to highlight the potential of its FABP5 inhibitor platform across multiple indications.